The human proteome includes many proteins that are fully disordered or that contain large disordered regions. Although these proteins are closely linked with a wide range of human diseases, no clinically-approved drug targets them in their monomeric forms. This situation arises, at least in part, from the current lack of understanding of the mechanisms by which small molecules can bind disordered proteins. To explore possible solutions to this problem, we discuss how an overall decrease in the free energy associated with intermolecular binding can originate from different combinations of enthalpic and entropic contributions. We then propose a mechanism of binding by which small molecules can affect the conformational space of a disordered protein by creating an entropic expansion of the system in which additional conformations of the protein are increasingly populated. This mechanism can be exploited in strategies to modulate the behaviour of disordered proteins, as even small changes in their conformational spaces can drastically affect their properties.
Small molecules binding to disordered proteins
Major advances have been recently made in understanding the molecular roles disordered proteins play in disease [6, 7, 18] . However, the development of therapeutics that target disordered proteins is still in its infancy, in part because the highly dynamic nature of these proteins renders them difficult to study experimentally. For example, in the case of Alzheimer's disease, despite the enormous efforts over the past two decades to develop drugs capable of inhibiting the aggregation process of the disordered amyloid β peptide, currently no compound that effectively does so has entered clinical use [18] [19] [20] . A recently proposed approach to obtain drugs targeting disordered regions relies on the computational docking of small-molecule fragments against an ensemble of representative conformations of the protein of interest [21] . Its application to α-synuclein, a disordered protein involved in Parkinson's disease, identified a compound that inhibits the aggregation of α-synuclein [21] . However, it is still poorly understood whether this compound binds directly to the monomeric protein rather than to its aggregated species. A clearer example of direct targeting of monomeric disordered proteins is the oncoprotein c-Myc [22] [23] [24] . High-throughput screening yielded a series of compounds interacting with its disordered regions, which prevent binding to its partner, Max. The mechanism of these drug-binding interactions, however, remains unclear and these compounds have not yet entered clinical use [22] [23] [24] 25] .
Disordered proteins populate ensembles of many conformations, each with its own occupation probability. The behaviour of disordered proteins is governed by these ensembles and can thus be drastically different from that of any individual conformation. Upon interacting with other molecules such as protein-binding partners, disordered proteins may pay an entropic cost because they restrict their conformation space in the bound form, which can be compensated by an enthalpic gain [11, 26] . Conversely, in an alternative scenario a change in the behaviour of disordered proteins may be achieved through the use of small molecules, such that the conformational space of a disordered protein is not restricted, but rather, entropically expanded (see Glossary) by new, transiently bound states with varying probabilities. In the following we discuss potential mechanisms through which small molecules could be effective at targeting monomeric disordered proteins.
Thermodynamics of protein-ligand binding
The binding of two molecules occurs spontaneously when it is associated with an overall decrease in free energy (∆ < 0), where ∆ indicates the difference between the free energy of the final state and that of the initial state. This difference can be expressed as the sum of enthalpic and entropic contributions
where the change in enthalpy (∆ ) is determined by a variety of interatomic forces, including electrostatic, van der Waals and hydrogen bonding interactions, and the entropic contribution (∆ ) represents the change in the size of the conformational space available to the overall system, including the protein, ligand, and solvent molecules.
Enthalpic and entropic factors can either contribute favorably or unfavorably to ∆ , resulting in the four possible modes: 1) ∆ > 0, ∆ < 0, 2) ∆ < 0, ∆ < 0, 3) ∆ < 0, ∆ > 0, and 4) ∆ > 0, ∆ > 0. Only modes 2-4 yield negative ∆ values, thus leading to binding.
Protein-ligand binding systems can be characterized experimentally into one of these four modes using, for example, isothermal titration calorimetry (ITC) [27] . ITC experiments allow direct, in-solution, label-free determination of both ∆ and ∆ for a protein-ligand binding system, including contributions from the solvent. The difference of these observed values can be used to calculate − ∆ using Eq. 1 [27] [28] [29] . While many protein-ligand binding events are driven by enthalpic factors, in some cases entropy can contribute favorably towards a negative change in free energy, and thus result in binding.
To better understand the role of entropy in protein-ligand binding interactions, we reviewed all entries in the Binding Database (BindingDB) for which there are ITC data (139 unique, non-mutant entries). We categorized these entries according to the magnitude of the entropic contributions [28, [30] [31] [32] [33] (Figure 2a) . Some enthalpically-favorable interactions come at an entropic cost (black points). This compromise is referred to as enthalpy-entropy compensation.
In rational drug design, it is possible to optimize the enthalpy to promote binding to a target, and occasionally the entropy is also optimized. This emphasis is reflected by the distribution of the entropic contributions to binding across the BindingDB (Figure 2b) . We note that strong entropic contributions to protein-ligand binding are highly underrepresented in the BindingDB. Furthermore, the vast majority of the entropically-favourable interactions in to phospholipase D αC2 [34] . The second is the binding of a Zn 2+ ion to conantokin-G or to conantokin-T [35] . These changes in entropy seem to be arising from conformational changes in the proteins themselves, rather than from released solvent molecules. More specifically, the binding of metal ions may expose hydrophobic groups to water, causing the backbones to behave in a disordered manner [34, 35] . The increased conformational flexibility enables the protein target to occupy more states, thereby increasing the entropy of the system (Figure 2c ).
Such induced disorder-upon-binding mechanisms have been proposed and validated for other
classes of proteins. For example, one ligand, PD173955, has been optimised to promote disorder of the Bcr-Abl kinase activation loop and therefore increases overall binding affinity as compared to its parent compound, imatinib [36] . Along similar lines, variable differences in the conformational entropy between free and bound states of galectin-3 have been observed upon binding to different carbohydrate differences. The extent of this induced conformational entropy has been shown to control the affinity [37] . These studies, among others, [38] [39] [40] [41] support the validity of ligand binding through entropic expansion for disordered proteins.
In contrast to traditional binding scenarios in which a drug locks a protein in an inactive state, the entropy-driven binding scenario may appear unconventional due to the multiplicity of low populated conformations in which the protein is weakly interacting with the ligand (Figure 2c ). This mechanism of interaction suggests a more general definition of 'binding' than one in which two molecules form a stable association through strong intermolecular interactions.
Within this framework any interaction in which a ligand significantly affects the conformational space of a protein may be considered binding. This view raises two issues (see Outstanding Questions Box): firstly, by this definition, solutes affecting protein hydration, high salt concentrations, and crowding agents that affect the conformational space of a disordered protein are be considered as 'ligands' even though they are not traditionally considered as such. Although discussing binding in this way may be unconventional, we are forced here to consider it because it is the natural consequence of entropic expansion.
A second concern is how these interactions can be specific, as binding interactions governed by a network of weaker interactions to induce favourable entropic changes may not be localized to a single binding region. We propose, however, that a combination of entropically and enthalpically favourable interactions can be used to optimize, specific interactions that can alter the behaviour of disordered regions. In other words, one way in which ligands may bind disordered regions consists of using relatively weak enthalpic interactions to ensure specificity, but relying on entropic factors for increasing the binding free energy. Mutagenesis studies have confirmed that drugs found to bind to the disordered region of c-Myc have specific binding regions 11-29 residues long within the 84-residue long disordered bHLHZip domain [42] , thus suggesting that specificity may be achievable when binding to disordered regions. However, it is possible that these small molecules may bind to other proteins as some of their constituent scaffolds have been shown to bind a large number of targets with weak or moderate affinity [43] .
Using entropy to target disordered proteins
Enthalpy-focused rational drug design, which is widely used for targeting globular proteins This concept may be used to rationalize simulations performed recently on a peptide fragment of c-Myc and its binding partner, the small molecule 10058-F4. The c-Myc peptide was observed to occupy an increasingly large number of low populated states upon binding 10058-F4 as compared to the unbound form [45] . We interpret this observation as an example of the extended conformational space of a bound disordered protein and thereby a potential increase in the overall entropy of the system. Similar analyses on another c-Myc peptide and its binding partner 10074-A4 further suggest that drug binding to c-Myc occurs weakly at many binding sites along the binding region [46] . These reports are consistent with the hypothesis of an entropy-increasing mechanism, as described above. Further studies will be necessary to confirm these conclusions.
Additionally, a second relevant example is the MDM2 protein, which contains a large disordered lid region. Upon binding some classes of p53/MDM2 antagonists, the base of the lid region becomes ordered via contacts with the ligand with an accompanying increase in flexibility of the remainder of the disordered region as compared to the disordered state [47, 48] . In the current attempts to curtail the toxic behavior of disordered proteins, likely milestones may include the fine-tuning of flexible disordered regions such as the flexible lid of MDM2.
Therapeutic potentials of the entropic expansion mechanism of binding
Conformational ensembles of disordered proteins are extremely sensitive to external factors.
Post-translational modifications [49] , point mutations [50] , and pH changes [51] can significantly reweight the states within an ensemble, including introducing nontrivial states and significantly decreasing the weights of existing ones. Small changes within ensembles can have profound physiological effects. In the case of mutational variants of α-synuclein, it was reported that relatively small differences in the ensembles, and more specifically in the populations of β-strands [50] and polyproline II [52] secondary structure elements, correspond to large differences in the aggregation rates, thus affecting the formation of neurotoxic species.
Small molecules can have a similar potential to change the ensembles of disordered proteins from one that is disease-promoting to one that may be disease-preventing, thereby enabling them to have a therapeutic effect. Earlier in this article, we described drug development opportunities aimed at entropically expanding the ensemble, although reweighting, restricting, or shifting the ensemble are also candidate strategies to change the behaviour of disordered proteins and eliminate disease-promoting conformations.
As is the case of c-Myc described earlier, drugs that target disordered regions have shown promising initial results both in vitro and in vivo, and currently more metabolically-stable analogs are in development [6, 23, 53] . An ability to modify the behaviour of disordered proteins via the use of small molecules may have profound implications for disease. For instance, the major neurotoxic agents responsible in Alzheimer's disease are soluble oligomeric species formed by the aggregation of the amyloid β peptide [20, 54, 55] . We thus believe that particularly effective therapeutic agents against aggregation may inhibit the formation of oligomeric assemblies via entropic expansion of monomeric disordered peptides.
Because many of the toxic oligomeric species involved in neurodegeneration are largely comprised of disordered proteins, reweighting the monomeric ensembles of these disordered proteins may slow down the formation of toxic oligomeric species. As new states are introduced, the populations of existing, potentially disease-promoting states will decrease, and such an expansion of the ensemble can be achieved by the introduction of certain small molecules that increase the entropy of the overall system.
Concluding remarks
In most cases the binding of ligands to structured proteins is either driven by enthalpic factors or by solvent-mediated entropic interactions such as hydrophobic attraction. In the case of disordered proteins, however, we expect that favourable entropic contributions arising from the proteins themselves rather than from the solvent may represent an alternative drugdiscovery strategy, which can be then further tunable using enthalpic contributions.
Disordered proteins have been considered as 'untargetable' so far because they do not readily lend themselves to enthalpy-driven binding, as no tight binding small-molecules have been identified to interact with them (see Outstanding Questions Box). They may be, however, more amenable to binding via entropic expansion, which may only require weak enthalpic interactions between proteins and ligands. We anticipate that by exploiting recent developments in experimental measurements and molecular dynamics simulations it will become possible to obtain increasingly accurate estimates of entropic contributions of disordered protein-ligand systems, which will hopefully facilitate the rational development of small molecules targeting disordered proteins. Entropic expansion. An increase of entropy of a disordered protein upon the introduction of a ligand, whereby the increase arises because the disordered protein populates even more states than it did in the unbound form.
Glossary

BindingDB (Binding Database
Isothermal titration calorimetry (ITC).
An experimental technique that can be used to determine thermodynamic parameters from a binding interaction. 
